Jean Bidlack
| Title | Professor |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Pharmacology and Physiology |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 711
Rochester NY 14642
|
|---|
|
|
|
| 1975 |
|
| Periclean Scholar Award | Skidmore College | | 1995 |
|
| Wallace O. Fenn Mentor Award | University of Rochester | | 1998 |
-
| 2008 | NIH Senior Scientist Award | National Institute of Health | | 2001 |
|
| The Alumni Award for Excellence in Graduate Education | University of Rochester | | 2004 |
|
| Periclean Alumna Scholar Award | Skidmore College | | 2005 |
|
| Distinguished Service Award | Society on NeuroImmune Pharmacology | | 2007 |
|
| Excellence in Research Award | University of Rochester | | 2007 |
|
| University Dean's Award for Meritorious Service in Ph.D. Defenses | University of Rochester | | 2010 |
|
| College of CSR Reviewers | National Institutes of Health |
-
Wentland MP, Jo S, Gargano JM, Vanalstine MA, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 8. High affinity ligands for opioid receptors in the picomolar K(i) range: Oxygenated N-(2-[1,1'-biphenyl]-4-ylethyl) analogues of 8-CAC. Bioorg Med Chem Lett. 2012 Dec 15; 22(24):7340-4.
-
Neumeyer JL, Zhang B, Zhang T, Sromek AW, Knapp BI, Cohen DJ, Bidlack JM. Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors. J Med Chem. 2012 Apr 26; 55(8):3878-90.
-
Li Y, Lefever MR, Muthu D, Bidlack JM, Bilsky EJ, Polt R. Opioid glycopeptide analgesics derived from endogenous enkephalins and endorphins. Future Med Chem. 2012 Feb; 4(2):205-26.
-
Dean RL, Eyerman D, Todtenkopf MS, Turncliff RZ, Bidlack JM, Deaver DR. Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats. Pharmacol Biochem Behav. 2012 Jan; 100(3):530-7.
-
Yeomans L, Muthu D, Lowery JJ, Martinez HN, Abrell L, Lin G, Strom K, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Phosphorylation of enkephalins: NMR and CD studies in aqueous and membrane-mimicking environments. Chem Biol Drug Des. 2011 Nov; 78(5):749-56.
-
Hough LB, Nalwalk JW, Yang J, Conroy JL, VanAlstine MA, Yang W, Gargano J, Shan Z, Zhang SZ, Wentland MP, Phillips JG, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, Ding X. Brain P450 epoxygenase activity is required for the antinociceptive effects of improgan, a nonopioid analgesic. Pain. 2011 Apr; 152(4):878-87.
-
Zhang B, Zhang T, Sromek AW, Scrimale T, Bidlack JM, Neumeyer JL. Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for ?, µ, and d opioid receptors. Bioorg Med Chem. 2011 May 1; 19(9):2808-16.
-
Zhang T, Yan Z, Sromek A, Knapp BI, Scrimale T, Bidlack JM, Neumeyer JL. Aminothiazolomorphinans with mixed ? and µ opioid activity. J Med Chem. 2011 Mar 24; 54(6):1903-13.
-
Balboni G, Salvadori S, Marczak ED, Knapp BI, Bidlack JM, Lazarus LH, Peng X, Si YG, Neumeyer JL. Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic. Eur J Med Chem. 2011 Feb; 46(2):799-803.
-
Lowery JJ, Raymond TJ, Giuvelis D, Bidlack JM, Polt R, Bilsky EJ. In vivo characterization of MMP-2200, a mixed d/µ opioid agonist, in mice. J Pharmacol Exp Ther. 2011 Mar; 336(3):767-78.
-
Conroy JL, Fang C, Gu J, Zeitlin SO, Yang W, Yang J, VanAlstine MA, Nalwalk JW, Albrecht PJ, Mazurkiewicz JE, Snyder-Keller A, Shan Z, Zhang SZ, Wentland MP, Behr M, Knapp BI, Bidlack JM, Zuiderveld OP, Leurs R, Ding X, Hough LB. Opioids activate brain analgesic circuits through cytochrome P450/epoxygenase signaling. Nat Neurosci. 2010 Mar; 13(3):284-6.
-
Fulton BS, Knapp BL, Bidlack JM, Neumeyer JL. Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1; 20(5):1507-9.
-
Decker M, Si YG, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14; 53(1):402-18.
-
Decker M, Fulton BS, Zhang B, Knapp BI, Bidlack JM, Neumeyer JL. Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10; 52(23):7389-96.
-
Wentland MP, Lou R, Lu Q, Bu Y, Denhardt C, Jin J, Ganorkar R, VanAlstine MA, Guo C, Cohen DJ, Bidlack JM. Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15; 19(8):2289-94.
-
Keyari CM, Knapp BI, Bidlack JM, Lowey J, Bilsky EJ, Polt R. Glycosyl-enkephalins: synthesis and binding at the mu, delta & kappa opioid receptors. Antinociception in mice. Adv Exp Med Biol. 2009; 611:495-6.
-
Wentland MP, Lu Q, Ganorkar R, Zhang SZ, Jo S, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants of cyclazocine. Bioorg Med Chem Lett. 2009 Jan 15; 19(2):365-8.
-
Mathews JL, Smrcka AV, Bidlack JM. A novel Gbetagamma-subunit inhibitor selectively modulates mu-opioid-dependent antinociception and attenuates acute morphine-induced antinociceptive tolerance and dependence. J Neurosci. 2008 Nov 19; 28(47):12183-9.
-
Wentland MP, Lou R, Lu Q, Bu Y, VanAlstine MA, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1; 19(1):203-8.
-
Bidlack JM, Morris HH. Phenobarbital withdrawal seizures may occur over several weeks before remitting: human data and hypothetical mechanism. Seizure. 2009 Jan; 18(1):79-81.
-
Fulton BS, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors. Bioorg Med Chem Lett. 2008 Aug 15; 18(16):4474-6.
-
Mathews JL, Fulton BS, Negus SS, Neumeyer JL, Bidlack JM. In vivo characterization of (-)(-)MCL-144 and (+)(-)MCL-193: isomeric, bivalent ligands with mu/kappa agonist properties. Neurochem Res. 2008 Oct; 33(10):2142-50.
-
Wentland MP, Sun X, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-carboxamidocyclazocine. Bioorg Med Chem. 2008 May 15; 16(10):5653-64.
-
Reed B, Bidlack JM, Chait BT, Kreek MJ. Extracellular biotransformation of beta-endorphin in rat striatum and cerebrospinal fluid. J Neuroendocrinol. 2008 May; 20(5):606-16.
-
VanAlstine MA, Wentland MP, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 5. Opioid receptor binding properties of N-((4'-phenyl)-phenethyl) analogues of 8-CAC. Bioorg Med Chem Lett. 2007 Dec 1; 17(23):6516-20.
-
Zhang A, Li F, Ding C, Yao Q, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and pharmacological evaluation of 6,7-indolo/thiazolo-morphinans--further SAR of levorphanol. J Med Chem. 2007 May 31; 50(11):2747-51.
-
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors. J Med Chem. 2007 May 3; 50(9):2254-8.
-
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15; 15(12):4106-12.
-
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15; 17(6):1508-11.
-
Lowery JJ, Yeomans L, Keyari CM, Davis P, Porreca F, Knapp BI, Bidlack JM, Bilsky EJ, Polt R. Glycosylation improves the central effects of DAMGO. Chem Biol Drug Des. 2007 Jan; 69(1):41-7.
-
Wentland MP, VanAlstine M, Kucejko R, Lou R, Cohen DJ, Parkhill AL, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. 4. Opioid receptor binding properties of 8-[N-(4'-phenyl)-phenethyl)carboxamido] analogues of cyclazocine and ethylketocycalzocine. J Med Chem. 2006 Sep 7; 49(18):5635-9.
-
Neumeyer JL, Peng X, Knapp BI, Bidlack JM, Lazarus LH, Salvadori S, Trapella C, Balboni G. New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7; 49(18):5640-3.
-
Bidlack JM, Khimich M, Parkhill AL, Sumagin S, Sun B, Tipton CM. Opioid receptors and signaling on cells from the immune system. J Neuroimmune Pharmacol. 2006 Sep; 1(3):260-9.
-
Nefzi A, Ostresh JM, Appel JR, Bidlack J, Dooley CT, Houghten RA. Identification of potent and highly selective chiral tri-amine and tetra-amine mu opioid receptors ligands: an example of lead optimization using mixture-based libraries. Bioorg Med Chem Lett. 2006 Aug 15; 16(16):4331-8.
-
Bonacci TM, Mathews JL, Yuan C, Lehmann DM, Malik S, Wu D, Font JL, Bidlack JM, Smrcka AV. Differential targeting of Gbetagamma-subunit signaling with small molecules. Science. 2006 Apr 21; 312(5772):443-6.
-
Sun B, Tipton CM, Bidlack JM. The expression of prodynorphin gene is down-regulated by activation with lipopolysaccharide in U-937 macrophage cells. J Neuroimmunol. 2006 May; 174(1-2):52-62.
-
Parkhill AL, Bidlack JM. Reduction of lipopolysaccharide-induced interleukin-6 production by the kappa opioid U50,488 in a mouse monocyte-like cell line. Int Immunopharmacol. 2006 Jun; 6(6):1013-9.
-
Peng X, Knapp BI, Bidlack JM, Neumeyer JL. Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors. J Med Chem. 2006 Jan 12; 49(1):256-62.
-
Bart G, Schluger JH, Borg L, Ho A, Bidlack JM, Kreek MJ. Nalmefene induced elevation in serum prolactin in normal human volunteers: partial kappa opioid agonist activity? Neuropsychopharmacology. 2005 Dec; 30(12):2254-62.
-
Zhen Z, Bradel-Tretheway B, Sumagin S, Bidlack JM, Dewhurst S. The human herpesvirus 6 G protein-coupled receptor homolog U51 positively regulates virus replication and enhances cell-cell fusion in vitro. J Virol. 2005 Sep; 79(18):11914-24.
-
Mathews JL, Peng X, Xiong W, Zhang A, Negus SS, Neumeyer JL, Bidlack JM. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties. J Pharmacol Exp Ther. 2005 Nov; 315(2):821-7.
-
Wentland MP, Sun X, Bu Y, Lou R, Cohen DJ, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 3: 8-Thiocarboxamido and 8-thioformamido derivatives of cyclazocine. Bioorg Med Chem Lett. 2005 May 16; 15(10):2547-51.
-
Wentland MP, Lu Q, Lou R, Bu Y, Knapp BI, Bidlack JM. Synthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone. Bioorg Med Chem Lett. 2005 Apr 15; 15(8):2107-10.
-
Stevenson GW, Wentland MP, Bidlack JM, Mello NK, Negus SS. Effects of the mixed-action kappa/mu opioid agonist 8-carboxamidocyclazocine on cocaine- and food-maintained responding in rhesus monkeys. Eur J Pharmacol. 2004 Dec 15; 506(2):133-41.
-
Zhen Z, Bradel-Tretheway BG, Dewhurst S, Bidlack JM. Transient overexpression of kappa and mu opioid receptors using recombinant adenovirus vectors. J Neurosci Methods. 2004 Jul 30; 136(2):133-9.
-
Csutoras C, Zhang A, Bidlack JM, Neumeyer JL. An investigation of the N-demethylation of 3-deoxymorphine and the affinity of the alkylation products to mu, delta, and kappa receptors. Bioorg Med Chem. 2004 May 15; 12(10):2687-90.
-
Zhang A, Xiong W, Hilbert JE, DeVita EK, Bidlack JM, Neumeyer JL. 2-aminothiazole-derived opioids. Bioisosteric replacement of phenols. J Med Chem. 2004 Apr 8; 47(8):1886-8.
-
Rusovici DE, Negus SS, Mello NK, Bidlack JM. Kappa-opioid receptors are differentially labeled by arylacetamides and benzomorphans. Eur J Pharmacol. 2004 Feb 6; 485(1-3):119-25.
-
Gekker G, Hu S, Wentland MP, Bidlack JM, Lokensgard JR, Peterson PK. Kappa-opioid receptor ligands inhibit cocaine-induced HIV-1 expression in microglial cells. J Pharmacol Exp Ther. 2004 May; 309(2):600-6.
-
Bidlack JM, Parkhill AL. Assay of G protein-coupled receptor activation of G proteins in native cell membranes using [35S]GTP gamma S binding. Methods Mol Biol. 2004; 237:135-43.
-
Zhang A, Xiong W, Bidlack JM, Hilbert JE, Knapp BI, Wentland MP, Neumeyer JL. 10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors. J Med Chem. 2004 Jan 1; 47(1):165-74.
-
Neumeyer JL, Zhang A, Xiong W, Gu XH, Hilbert JE, Knapp BI, Negus SS, Mello NK, Bidlack JM. Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors. J Med Chem. 2003 Nov 20; 46(24):5162-70.
-
Zhou Q, Duan WH, Cohen DJ, Bidlack JM, Wentland MP. Synthesis and pharmacology of 8-amino-3-[(tetrahydro-2-furanyl)methyl] benzomorphan. Yao Xue Xue Bao. 2003 Oct; 38(10):748-53.
-
Kuehne ME, He L, Jokiel PA, Pace CJ, Fleck MW, Maisonneuve IM, Glick SD, Bidlack JM. Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J Med Chem. 2003 Jun 19; 46(13):2716-30.
-
Wentland MP, Sun X, Ye Y, Lou R, Bidlack JM. Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 2: 8-formamidocyclazocine analogues. Bioorg Med Chem Lett. 2003 Jun 2; 13(11):1911-4.
-
Bowen CA, Negus SS, Zong R, Neumeyer JL, Bidlack JM, Mello NK. Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys. Neuropsychopharmacology. 2003 Jun; 28(6):1125-39.
-
Wentland MP, Ye Y, Cioffi CL, Lou R, Zhou Q, Xu G, Duan W, Dehnhardt CM, Sun X, Cohen DJ, Bidlack JM. Syntheses and opioid receptor binding affinities of 8-amino-2,6-methano-3-benzazocines. J Med Chem. 2003 Feb 27; 46(5):838-49.
-
Negus SS, Bidlack JM, Mello NK, Furness MS, Rice KC, Brandt MR. Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol. 2002 Nov; 13(7):557-70.
-
Parkhill AL, Bidlack JM. Several delta-opioid receptor ligands display no subtype selectivity to the human delta-opioid receptor. Eur J Pharmacol. 2002 Sep 20; 451(3):257-64.
-
Bidlack JM, Cohen DJ, McLaughlin JP, Lou R, Ye Y, Wentland MP. 8-Carboxamidocyclazocine: a long-acting, novel benzomorphan. J Pharmacol Exp Ther. 2002 Jul; 302(1):374-80.
-
Neumeyer JL, Gu XH, van Vliet LA, DeNunzio NJ, Rusovici DE, Cohen DJ, Negus SS, Mello NK, Bidlack JM. Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan. Bioorg Med Chem Lett. 2001 Oct 22; 11(20):2735-40.
-
Suzuki S, Chuang LF, Doi RH, Bidlack JM, Chuang RY. Kappa-opioid receptors on lymphocytes of a human lymphocytic cell line: morphine-induced up-regulation as evidenced by competitive RT-PCR and indirect immunofluorescence. Int Immunopharmacol. 2001 Sep; 1(9-10):1733-42.
-
Wentland MP, Lou R, Dehnhardt CM, Duan W, Cohen DJ, Bidlack JM. 3-Carboxamido analogues of morphine and naltrexone. synthesis and opioid receptor binding properties. Bioorg Med Chem Lett. 2001 Jul 9; 11(13):1717-21.
-
Peterson PK, Gekker G, Lokensgard JR, Bidlack JM, Chang AC, Fang X, Portoghese PS. Kappa-opioid receptor agonist suppression of HIV-1 expression in CD4+ lymphocytes. Biochem Pharmacol. 2001 May 1; 61(9):1145-51.
-
Wentland MP, Lou R, Ye Y, Cohen DJ, Richardson GP, Bidlack JM. 8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Bioorg Med Chem Lett. 2001 Mar 12; 11(5):623-6.
-
Martin-Kleiner I, Bidlack JM. Chronic opioid treatment of the mouse thymoma cell lines R1.G1 and R1EGO leads to down-regulation of the kappa opioid receptor without desensitization of adenylyl cyclase activity. Int Immunopharmacol. 2001 Jan; 1(1):13-20.
-
Bidlack JM, Abraham MK. Mitogen-induced activation of mouse T cells increases kappa opioid receptor expression. Adv Exp Med Biol. 2001; 493:103-10.
-
Wentland MP, Duan W, Cohen DJ, Bidlack JM. Selective protection and functionalization of morphine: synthesis and opioid receptor binding properties of 3-amino-3-desoxymorphine derivatives. J Med Chem. 2000 Sep 21; 43(19):3558-65.
-
Bidlack JM. Detection and function of opioid receptors on cells from the immune system. Clin Diagn Lab Immunol. 2000 Sep; 7(5):719-23.
-
Neumeyer JL, Mello NK, Negus SS, Bidlack JM. Kappa opioid agonists as targets for pharmacotherapies in cocaine abuse. Pharm Acta Helv. 2000 Mar; 74(2-3):337-44.
-
Wentland MP, Xu G, Cioffi CL, Ye Y, Duan W, Cohen DJ, Colasurdo AM, Bidlack JM. 8-Aminocyclazocine analogues: synthesis and structure-activity relationships. Bioorg Med Chem Lett. 2000 Jan 17; 10(2):183-7.
-
Neumeyer JL, Bidlack JM, Zong R, Bakthavachalam V, Gao P, Cohen DJ, Negus SS, Mello NK. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence. J Med Chem. 2000 Jan 13; 43(1):114-22.
-
Bidlack JM, Jadrovski I. Pharmacological profiles of kappa opioids. Correlation between [35S]GTP gamma S binding and cyclic AMP production. Ann N Y Acad Sci. 2000; 909:264.
-
Bidlack JM, McLaughlin JP, Wentland MP. Partial opioids. Medications for the treatment of pain and drug abuse. Ann N Y Acad Sci. 2000; 909:1-11.
-
Xie W, Samoriski GM, McLaughlin JP, Romoser VA, Smrcka A, Hinkle PM, Bidlack JM, Gross RA, Jiang H, Wu D. Genetic alteration of phospholipase C beta3 expression modulates behavioral and cellular responses to mu opioids. Proc Natl Acad Sci U S A. 1999 Aug 31; 96(18):10385-90.
-
Ignatowski TA, Bidlack JM. Differential kappa-opioid receptor expression on mouse lymphocytes at varying stages of maturation and on mouse macrophages after selective elicitation. J Pharmacol Exp Ther. 1999 Aug; 290(2):863-70.
-
McLaughlin JP, Hill KP, Jiang Q, Sebastian A, Archer S, Bidlack JM. Nitrocinnamoyl and chlorocinnamoyl derivatives of dihydrocodeinone: in vivo and in vitro characterization of mu-selective agonist and antagonist activity. J Pharmacol Exp Ther. 1999 Apr; 289(1):304-11.
-
Martin-Kleiner I, Bidlack JM. The synthetic kappa-opioid agonist (-)U50,488 does not affect calcium transport into R1.1 mouse thymoma cell line. Int J Immunopharmacol. 1999 Feb; 21(2):133-40.
-
Dooley CT, Ny P, Bidlack JM, Houghten RA. Selective ligands for the mu, delta, and kappa opioid receptors identified from a single mixture based tetrapeptide positional scanning combinatorial library. J Biol Chem. 1998 Jul 24; 273(30):18848-56.
-
Sharp BM, Roy S, Bidlack JM. Evidence for opioid receptors on cells involved in host defense and the immune system. J Neuroimmunol. 1998 Mar 15; 83(1-2):45-56.
-
Xu JY, Hill KP, Bidlack JM. The nitric oxide/cyclic GMP system at the supraspinal site is involved in the development of acute morphine antinociceptive tolerance. J Pharmacol Exp Ther. 1998 Jan; 284(1):196-201.
-
Ignatowski TA, Bidlack JM. Changes in kappa opioid receptor expression during maturation of mouse lymphocytes. Adv Exp Med Biol. 1998; 437:117-24.
-
Ignatowski TA, Bidlack JM. Detection of kappa opioid receptors on mouse thymocyte phenotypic subpopulations as assessed by flow cytometry. J Pharmacol Exp Ther. 1998 Jan; 284(1):298-306.
-
Lawrence DM, Hutchinson I, Seyed-Mozaffari A, Archer S, Bidlack JM. Fluorescent staining of kappa opioid receptors using naltrexamine derivatives and phycoerythrin. J Immunol Methods. 1997 Feb 28; 201(2):173-81.
-
McLaughlin JP, Sebastian A, Archer S, Bidlack JM. 14 beta-Chlorocinnamoylamino derivatives of metopon: long-term mu-opioid receptor antagonists. Eur J Pharmacol. 1997 Feb 12; 320(2-3):121-9.
-
Xu JY, Seyed-Mozaffari A, Archer S, Bidlack JM. N-cyclobutylmethyl analog of normorphinone, N-CBM-TAMO: a short-term opioid agonist and long-term Mu-selective irreversible opioid antagonist. J Pharmacol Exp Ther. 1996 Nov; 279(2):539-47.
-
Archer S, Glick SD, Bidlack JM. Cyclazocine revisited. Neurochem Res. 1996 Nov; 21(11):1369-73.
-
Gatch MB, Negus SS, Mello NK, Archer S, Bidlack JM. Effects of the structurally novel opioid 14 alpha, 14' beta-[dithiobis [(2-oxo-2,1-ethanediyl)imino]]bis(7,8-dihydromorphinone) on schedule-controlled behavior and thermal nociception in rhesus monkeys. J Pharmacol Exp Ther. 1996 Sep; 278(3):1282-9.
-
Chao CC, Gekker G, Hu S, Sheng WS, Shark KB, Bu DF, Archer S, Bidlack JM, Peterson PK. kappa opioid receptors in human microglia downregulate human immunodeficiency virus 1 expression. Proc Natl Acad Sci U S A. 1996 Jul 23; 93(15):8051-6.
-
Schultz AG, Wang A, Alva C, Sebastian A, Glick SD, Deecher DC, Bidlack JM. Asymmetric syntheses, opioid receptor affinities, and antinociceptive effects of 8-amino-5,9-methanobenzocyclooctenes, a new class of structural analogues of the morphine alkaloids. J Med Chem. 1996 May 10; 39(10):1956-66.
-
Bidlack JM, Lawrence DM, Ignatowski TA. Kappa Opioid receptors on immune cells as studied by fluorescent ligands. Adv Exp Med Biol. 1996; 402:13-22.
-
McLaughlin JP, Nowak D, Sebastian A, Schultz AG, Archer S, Bidlack JM. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors. Eur J Pharmacol. 1995 Dec 27; 294(1):201-6.
-
Jiang Q, Seyed-Mozaffari A, Sebastian A, Archer S, Bidlack JM. Preventing morphine antinociceptive tolerance by irreversible mu opioid antagonists before the onset of their antagonism. J Pharmacol Exp Ther. 1995 May; 273(2):680-8.
-
Dooley CT, Kaplan RA, Chung NN, Schiller PW, Bidlack JM, Houghten RA. Six highly active mu-selective opioid peptides identified from two synthetic combinatorial libraries. Pept Res. 1995 May-Jun; 8(3):124-37.
-
Joseph DB, Bidlack JM. The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line down-regulates without desensitizing during chronic opioid exposure. J Pharmacol Exp Ther. 1995 Mar; 272(3):970-6.
-
Lawrence DM, el-Hamouly W, Archer S, Leary JF, Bidlack JM. Identification of kappa opioid receptors in the immune system by indirect immunofluorescence. Proc Natl Acad Sci U S A. 1995 Feb 14; 92(4):1062-6.
-
Lawrence DM, Joseph DB, Bidlack JM. Kappa opioid receptors expressed on three related thymoma cell lines. Differences in receptor-effector coupling. Biochem Pharmacol. 1995 Jan 6; 49(1):81-9.
-
Lawrence DM, Archer S, Bidlack JM. Identification of opioid receptors in the immune system using a novel combination of selective opioid ligands and indirect phycoerythrin immunofluorescence. Adv Exp Med Biol. 1995; 373:17-21.
-
Bidlack JM, Joseph DB, Lawrence DM. Kappa opioid receptors on three related thymoma cell lines. Differences in receptor-effector coupling. Adv Exp Med Biol. 1995; 373:23-7.
-
Dooley CT, Chung NN, Wilkes BC, Schiller PW, Bidlack JM, Pasternak GW, Houghten RA. An all D-amino acid opioid peptide with central analgesic activity from a combinatorial library. Science. 1994 Dec 23; 266(5193):2019-22.
-
Archer S, Seyed-Mozaffari A, Jiang Q, Bidlack JM. 14 alpha,14' beta-[Dithiobis[(2-oxo-2,1-ethanediyl)imino]]bis (7,8-dihydromorphinone) and 14 alpha,14' beta-[dithiobis[(2-oxo-2,1- ethanediyl)imino]]bis[7,8-dihydro-N-(cyclopropylmethyl)normorphinone]: chemistry and opioid binding properties. J Med Chem. 1994 May 27; 37(11):1578-85.
-
Joseph DB, Bidlack JM. The kappa-opioid receptor expressed on the mouse lymphoma cell line R1.1 contains a sulfhydryl group at the binding site. Eur J Pharmacol. 1994 Mar 15; 267(1):1-6.
-
Jiang Q, Sebastian A, Archer S, Bidlack JM. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone and its corresponding N-cyclopropylmethyl analog, N-cyclopropylmethylnor-5 beta-methyl-14 beta-(p-nitrocinnamoylamino)- 7,8-dihydromorphinone: mu-selective irreversible opioid antagonists. J Pharmacol Exp Ther. 1994 Mar; 268(3):1107-13.
-
Sebastian A, Bidlack JM, Jiang Q, Deecher D, Teitler M, Glick SD, Archer S. 14 beta-[(p-nitrocinnamoyl)amino]morphinones, 14 beta-[(p-nitrocinnamoyl)amino]-7,8-dihydromorphinones, and their codeinone analogues: synthesis and receptor activity. J Med Chem. 1993 Oct 15; 36(21):3154-60.
-
Lawrence DM, Bidlack JM. The kappa opioid receptor expressed on the mouse R1.1 thymoma cell line is coupled to adenylyl cyclase through a pertussis toxin-sensitive guanine nucleotide-binding regulatory protein. J Pharmacol Exp Ther. 1993 Sep; 266(3):1678-83.
-
Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM. Antinociceptive evaluation of 14 beta-(bromoacetamido)-7,8-dihydro- N(cyclopropylmethyl)-normorphinone in mice. Eur J Pharmacol. 1993 Aug 24; 240(2-3):201-6.
-
Bidlack JM, Kaplan RA, Subbramanian RA, Seyed-Mozaffari A, Archer S. Affinity labeling of the mu opioid receptor in bovine striatal membranes with [3H]-14 beta-(bromoacetamido)-7,8-dihydromorphine. Biochemistry. 1993 Jul 6; 32(26):6703-11.
-
Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM. Pharmacological study of 14 beta-(thioglycolamido)-7,8-dihydro-N(cyclopropylmethyl)-normor phinone (N-CPM-TAMO). J Pharmacol Exp Ther. 1993 Mar; 264(3):1021-7.
-
Jiang Q, Sebastian A, Archer S, Bidlack JM. 5 beta-Methyl-14 beta-(p-nitrocinnamoylamino)-7,8-dihydromorphinone: a long-lasting mu-opioid receptor antagonist devoid of agonist properties. Eur J Pharmacol. 1993 Jan 5; 230(1):129-30.
-
Lawrence DM, Bidlack JM. Kappa opioid binding sites on the R1.1 murine lymphoma cell line: sensitivity to cations and guanine nucleotides. J Neuroimmunol. 1992 Dec; 41(2):223-30.
-
Bidlack JM, Saripalli LD, Lawrence DM. kappa-Opioid binding sites on a murine lymphoma cell line. Eur J Pharmacol. 1992 Nov 2; 227(3):257-65.
-
Selley DE, Bidlack JM. Effects of beta-endorphin on mu and delta opioid receptor-coupled G-protein activity: low-Km GTPase studies. J Pharmacol Exp Ther. 1992 Oct; 263(1):99-104.
-
Gucker S, Bidlack JM. Protein kinase C activation increases the rate and magnitude of agonist-induced delta-opioid receptor down-regulation in NG108-15 cells. Mol Pharmacol. 1992 Oct; 42(4):656-65.
-
Jiang Q, Seyed-Mozaffari A, Archer S, Bidlack JM. Antinociceptive properties of two alkylating derivatives of morphinone: 14 beta-(thioglycolamido)-7,8-dihydromorphinone (TAMO) and 14 beta-(bromoacetamido)-7,8-dihydromorphinone (H2BAMO). J Pharmacol Exp Ther. 1992 Aug; 262(2):526-31.
-
Hemmick LM, Bidlack JM. Endorphin peptides enhance mitogen-induced T cell proliferation which has been suppressed by prostaglandins. Adv Exp Med Biol. 1991; 288:211-4.
-
Hemmick LM, Bidlack JM. Beta-endorphin stimulates rat T lymphocyte proliferation. J Neuroimmunol. 1990 Sep-Oct; 29(1-3):239-48.
-
Grandy DK, Hanneman E, Bunzow J, Shih M, Machida CA, Bidlack JM, Civelli O. Purification, cloning, and tissue distribution of a 23-kDa rat protein isolated by morphine affinity chromatography. Mol Endocrinol. 1990 Sep; 4(9):1370-6.
-
Archer S, Bidlack J, Mulholland GK. Opium alkaloids and affinity labels. NIDA Res Monogr. 1990; 96:21-34.
-
Bidlack JM, Hemmick LM. Morphine enhancement of mitogen-induced T-cell proliferation. Prog Clin Biol Res. 1990; 328:405-8.
-
Bidlack JM, Frey DK, Kaplan RA, Seyed-Mozaffari A, Archer S. Affinity labeling of mu opioid receptors by sulfhydryl alkylating derivatives of morphine and morphinone. Mol Pharmacol. 1990 Jan; 37(1):50-9.
-
Selley DE, Bidlack JM. Guanine nucleotide regulation of [125I]beta-endorphin binding to NG108-15 and SK-N-SH cell membranes: specific cation requirements. Brain Res. 1989 Jul 24; 493(1):23-32.
-
Hemmick LM, Bidlack JM. Beta-endorphin suppresses rat plaque-forming cell response by a non-opioid mechanism. J Neuroimmunol. 1989 Jun; 23(1):67-71.
-
Bidlack JM, Frey DK, Seyed-Mozaffari A, Archer S. 14 beta-(Bromoacetamido)morphine irreversibly labels mu opioid receptors in rat brain membranes. Biochemistry. 1989 May 16; 28(10):4333-9.
-
Selley DE, Bidlack JM. Cation requirement for GTP regulation of [125I]b-endorphin binding to Mu and sigma opioid receptors. NIDA Res Monogr. 1989; 95:537-8.
-
Bidlack JM, Frey DK, Seyed-Mozaffari A, Archer S. Irreversible affinity ligands for mu opioid receptors. NIDA Res Monogr. 1989; 95:296.
-
Tyler CB, Bidlack JM. Inhibition of (+)[3H]SKF 10,047 binding to rat brain membranes by FAB fragments from a monoclonal antibody directed against the opioid receptor. Neurochem Res. 1988 Aug; 13(8):729-35.
-
Selley DE, Tyler CB, Bidlack JM. Guanine nucleotide regulation of [125I]beta-endorphin binding to rat brain membranes: monovalent cation requirement. J Neurochem. 1988 Jun; 50(6):1844-50.
-
Bidlack JM, O'Malley WE, Schulz R. Comparison of [125I]beta-endorphin binding to rat brain and NG108-15 cells using a monoclonal antibody directed against the opioid receptor. Mol Pharmacol. 1988 Feb; 33(2):170-7.
-
Hemmick LM, Bidlack JM. Beta-endorphin modulation of mitogen-stimulated calcium uptake by rat thymocytes. Life Sci. 1987 Oct 19; 41(16):1971-8.
-
Civelli O, Machida C, Bunzow J, Albert P, Hanneman E, Salon J, Bidlack J, Grandy D. The next frontier in the molecular biology of the opioid system. The opioid receptors. Mol Neurobiol. 1987; 1(4):373-91.
-
Bidlack JM, O'Malley WE. Inhibition of mu and delta but not kappa opioid binding to membranes by Fab fragments from a monoclonal antibody directed against the opioid receptor. J Biol Chem. 1986 Dec 5; 261(34):15844-9.
-
Bidlack JM, Mabie PC. Preparation of Fab fragments from a mouse monoclonal IgM. J Immunol Methods. 1986 Jul 24; 91(2):157-62.
-
Rudick RA, Pallant A, Bidlack JM, Herndon RM. Free kappa light chains in multiple sclerosis spinal fluid. Ann Neurol. 1986 Jul; 20(1):63-9.
-
Bidlack JM. Binding to mu and delta opioid sites but not kappa sites is inhibited by Fab fragments from a monoclonal antibody directed against the opioid receptor. NIDA Res Monogr. 1986; 75:21-4.
-
Bidlack JM, Denton RR. A monoclonal antibody capable of modulating opioid binding to rat neural membranes. J Biol Chem. 1985 Dec 15; 260(29):15655-61.
-
Rudick RA, Peter DR, Bidlack JM, Knutson DW. Multiple sclerosis: free light chains in cerebrospinal fluid. Neurology. 1985 Oct; 35(10):1443-9.
-
Rudick RA, Bidlack JM, Knutson DW. Multiple sclerosis. Cerebrospinal fluid immune complexes that bind C1q. Arch Neurol. 1985 Sep; 42(9):856-8.
-
Bidlack JM, Denton RR. A monoclonal antibody directed against an opiate binding site in rat neural membranes. Neuropeptides. 1984 Dec; 5(1-3):225-8.
-
Harwell LW, Bolognino M, Bidlack JM, Knapp RJ, Lord EM. A freezing method for cell fusions to distribute and reduce labor and permit more thorough early evaluation of hybridomas. J Immunol Methods. 1984 Jan 20; 66(1):59-67.
-
Archer S, Seyed-Mozaffari A, Osei-Gyimah P, Bidlack JM, Abood LG. 14 beta-(2-bromoacetamido)morphine and 14 beta-(2-bromoacetamido)morphinone. J Med Chem. 1983 Dec; 26(12):1775-7.
-
Bidlack JM, Abood LG. Molecular characteristics of brain opiate and nicotine receptors. Biomembranes. 1983; 11:415-37.
-
Bidlack JM, Denton RR, Harwell LW. Generating monoclonal antibodies to the opioid receptor. Life Sci. 1983; 33 Suppl 1:151-4.
-
Bidlack JM, Ambudkar IS, Shamoo AE. Purification of phospholamban, a 22,000-dalton protein from cardiac sarcoplasmic reticulum that is specifically phosphorylated by cyclic AMP-dependent protein kinase. J Biol Chem. 1982 Apr 25; 257(8):4501-6.
-
Bidlack JM, Abood LG, Munemitsu SM, Archer S, Gala D, Kreilick RW. Affinity labeling and purification of the opiate receptor from rat brain. Adv Biochem Psychopharmacol. 1982; 33:301-9.
-
Bidlack JM, Abood LG, Osei-Gyimah P, Archer S. Purification of the opiate receptor from rat brain. Proc Natl Acad Sci U S A. 1981 Jan; 78(1):636-9.
-
Abood LG, Reynolds DT, Booth H, Bidlack JM. Sites and mechanisms for nicotine's action in the brain. Neurosci Biobehav Rev. 1981; 5(4):479-86.
-
Abood LG, Reynolds DT, Bidlack JM. Stereospecific 3H-nicotine binding to intact and solubilized rat brain membranes and evidence for its noncholinergic nature. Life Sci. 1980 Oct 6; 27(14):1307-14.
-
Bidlack JM, Shamoo AE. Adenosine 3',5'-monophosphate-dependent phosphorylation of a 6000 and a 22,000 dalton protein from cardiac sarcoplasmic reticulum. Biochim Biophys Acta. 1980 Oct 1; 632(2):310-25.
-
Bidlack JM, Abood LG. Solubilization of the opiate receptor. Life Sci. 1980 Jul 28; 27(4):331-40.
-
Bidlack JM, Lockshin RA. Evolution of LDH isozymes during programmed cell death. Comp Biochem Physiol B. 1976; 55(2):161-6.
|
Bidlack's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
